PhRMA Points To Key Areas Where Transparency Could Be Hiked In Drug Negotiations

By Maaisha Osman / February 7, 2025 at 3:16 PM

After CMS signaled it hopes to improve transparency in the Medicare drug price negotiation program, the Pharmaceutical Research and Manufacturers of America (PhRMA) pointed Inside Health Policy to key areas the brand drug lobby has suggested in past comments where the agency could enhance its transparency efforts.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

PhRMA Points To Key Areas Where Transparency Could Be Hiked In Drug Negotiations

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.